Cerebrae

Cerebrae

Financial solutions for healthcare providers and insurers

About Cerebrae

Simplify's Rating
Why Cerebrae is rated
B-
Rated C on Competitive Edge
Rated B on Growth Potential
Rated B on Differentiation

Industries

Fintech

Financial Services

Healthcare

Company Size

1-10

Company Stage

Series A

Total Funding

$16.5M

Headquarters

San Francisco, California

Founded

2019

Overview

Cerebrae provides financial solutions tailored for the healthcare industry, focusing on helping healthcare providers and insurers manage financial risks and opportunities. Its platform includes tools for pricing, underwriting, contracting, and actuarial analytics, allowing clients to track savings, monitor financial performance, and model return on investment (ROI). The primary clients are those implementing Value-Based Care (VBC) strategies, where payment is based on patient health outcomes rather than service volume. Cerebrae assists these clients in customizing their VBC strategies, evaluating contracts, and assessing financial risks associated with risk-sharing revenue models. Unlike many competitors, Cerebrae operates on a subscription-based model, offering a comprehensive suite of tools that enhance financial operations and risk management. The company's goal is to optimize financial performance for healthcare providers and insurers as they transition to value-based care.

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing adoption of AI enhances Cerebrae's actuarial analytics capabilities.
  • Telehealth data streams improve ROI calculations for value-based care contracts.
  • Personalized medicine trends align with Cerebrae's expansion opportunities.

What critics are saying

  • Increasing competition may erode Cerebrae's market share.
  • Regulatory changes could increase operational costs for platform updates.
  • Economic downturns may reduce spending on subscription-based platforms.

What makes Cerebrae unique

  • Cerebrae offers a unique platform for managing financial risks in healthcare.
  • The platform includes tools for pricing, underwriting, and actuarial analytics.
  • Cerebrae collaborates with Sera Prognostics for innovative value-based care solutions.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$16.5M

Above

Industry Average

Funded Over

0 Rounds

Company News

PR Newswire
Oct 4th, 2022
Sonrava Health To Include The Pretrm® Test In Its Employee Maternity Benefits Package In Collaboration With Cerebrae And Sera Prognostics

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm. SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif., Oct. 4, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, Sonrava Health, a national family of health and wellness companies, and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera's PreTRM® Test to members of Sonrava Health's employer-sponsored health insurance program. The PreTRM® Test is the only broadly clinically validated, commercially available blood test that provides an early, individual risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies. Sera's PreTRM® Test identifies nearly 90% of pregnancies where spontaneous preterm deliveries will occur, enabling earlier proactive intervention designed to improve the well-being of mothers and babies

There are no jobs for Cerebrae right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →